OC000459 is a once-daily oral CRTH2 antagonist in Phase IIb clinical trials that has demonstrated efficacy in asthma, allergic rhinitis and allergic conjunctivitis along with an excellent safety profile.

June 21, 2017

prudect name : OC000459 is a once-daily oral CRTH2 antagonist in Phase IIb clinical trials that has demonstrated efficacy in asthma, allergic rhinitis and allergic conjunctivitis along with an excellent safety profile.
OC000459

Synonyms: CAS NO: 851723-84-7Molecular Formula: C₂₁H₁₇FN₂O₂Molecular Weight: 348.37Purity: 98% minSolubility: In DMSOStorage: −20°C

web site: www.medchemexpress.com

References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18538560